2023/05/12 - Products

DailyDerma: a new routine for long-lasting relief for atopic dogs

Vignette_Corpo_DailyDerma.pngAtopic dermatitis is an inflammatory skin disease that affects 10% of dogs1. Very disabling for the animal, it is also complex to diagnose and treat. To improve its management, our teams have developed DailyDerma: an innovative programme that brings together veterinarians and owners for better long-term management of the disease.

Atopic dermatitis (AD) is the number one disease in dogs and the number one reason for veterinary visits after vaccination. It is caused by a combination of genetic, environmental and immune factors. Dogs with AD have a genetic predisposition to generate allergic reactions to external substances (allergens), in particular house dust mites. As the animal is always in contact with these allergens, the disease poses a long-term management problem, requiring ongoing treatment and care throughout the year and the animal's life, with many possible relapses. Atopic dogs often scratch and bite in specific areas, such as the paws, belly, face and ears. In 80% of cases, AD is also accompanied by external otitis. Although not fatal, AD can therefore be both disabling and painful for the animal and affect its well-being throughout its life. 

A global and individualised approach!
Dry, alopecic and itchy skin, itching, inflammatory lesions, ear infections... The symptoms of atopic dermatitis can vary from one dog to another, which makes both the diagnosis and treatment of the disease complex. In order to neutralise the inflammation and restore the skin barrier, it is necessary to take into account the dog as a whole and adapt the treatment to his particular case. Medication, emollient shampoos, specific foods enriched with essential fatty acids or anti-oxidants... the therapeutic arsenal is wide, but regular monitoring of the disease and adjustment of the treatment are key to ensuring the best possible quality of life for affected dogs. This is why the effectiveness of long-term management depends on active cooperation between vets and owners. 

DailyDerma: for vets and owners 
In order to improve the management of atopic dermatitis our teams have developed an innovative programme: DailyDerma. What makes it special? To offer veterinarians a new and effective routine in their dermatological practice and to strengthen cooperation with the owners of atopic dogs by facilitating their role in monitoring the disease. This is done in three key stages: short-term management of symptoms, in-depth exploration of their origin and long-term management of the disease.  In addition to a wide range of products and services to help with prevention, diagnosis and long-term treatment monitoring, the programme also includes a mobile application. It allows owners and veterinarians to exchange multiple information on the evolution of the disease as well as pictures of the lesions in real time. In this way, no information is forgotten during follow-up appointments. 

Pierre Jasmin, Global Head of Pet Dermatology: "With DailyDerma, we want to create a real relationship of trust with vets and owners by helping them to manage atopic dermatitis, day after day. Diagnostic tools, documentation, explanatory videos, a wide range of health solutions... Our teams provide their expertise and know-how to provide the most complete offer possible and enrich the management of atopic dermatitis in the long term."

Our programme has the ambition to be gradually implemented on a global scale. The latest stage was the World Veterinary Association Congress in Taiwan from 26 to 29 April, which enabled us to present it to the professionals present. In the run-up to the congress, our teams at Virbac Taiwan put together an unprecedented intensive programme, bringing together nearly 50 international experts to train in the approach and share best practices in veterinary dermatology. With DailyDerma, we want to work together for a better management of atopic dermatitis in the long term.

1 Dr Emmanuel Bensignor Bull. Acad. nat. med. 2010, 194, no 7, 1357-1364, meeting of 19 October 2010